Experiments show promising results for a drug that could lead to a lasting treatment for millions of Americans with macular degeneration.
Researchers at the University of North Carolina School of Medicine today published new findings in the hunt for a better treatment for macular degeneration. In studies using mice, a class of drugs known as MDM2 inhibitors proved highly effective at regressing the abnormal blood vessels responsible for the vision loss associated with the disease.
“We believe we may have found an optimized treatment for macular degeneration,” said senior study author Sai Chavala, MD, director of the Laboratory for Retinal Rehabilitation and assistant professor of Ophthalmology and Cell Biology & Physiology at the UNC School of Medicine. “Our hope is that MDM2 inhibitors would reduce the treatment burden on both patients and physicians.”
The research appeared Sept. 9, 2013 in the Journal of Clinical Investigation.
As many as 11 million Americans have some form of macular degeneration, which is the most common cause of central vision loss in the western world. Those with the disease find many daily activities such as driving, reading and watching TV increasingly difficult.
Currently, the best available treatment for macular degeneration is an antibody called anti-VEGF that is injected into the eye. Patients must visit their doctor for a new injection every 4-8 weeks, adding up to significant time and cost.
“The idea is we’d like to have a long-lasting treatment so patients wouldn’t have to receive as many injections,” said Chavala. “That would reduce their overall risk of eye infections, and also potentially lower the economic burden of this condition by reducing treatment costs.” Chavala practices at the Kittner Eye Center at UNC Health Care in Chapel Hill and New Bern.
All patients with age-related macular degeneration start out with the “dry” form of the disease, which can cause blurred vision or blind spots. In about 20 percent of patients, the disease progresses to its “wet” form, in which abnormal blood vessels form in the eye and begin to leak fluid or blood, causing vision loss.
While anti-VEGF works by targeting the growth factors that lead to leaky blood vessels, MDM2 inhibitors target the abnormal blood vessels themselves causing them to regress — potentially leading to a lasting effect.
Chavala and his colleagues investigated the effects of MDM2 inhibitors in cell culture and in a mouse model of macular degeneration. They found that the drug abolishes the problematic blood vessels associated with wet macular degeneration by activating a protein known as p53. “p53 is a master regulator that determines if a cell lives or dies. By activating p53, we can initiate the cell death process in these abnormal blood vessels,” said Chavala.
The Latest on: Macular degeneration
One-of-a-kind surgery conducted to treat Age Related Macular Degenration
on April 20, 2018 at 2:18 am
MaxiVision Super Specialty Eye Hospital, Hyderabad accomplished a milestone by performing its first ARMD (Age Related Macular Degeneration) surgery, a-first-of its kind operation in India. Dr Kasu Prasad Reddy, Founder of Maxivision Eye Hospital Group ... […]
Photodynamic Therapy-Induced Macular Hole
on April 19, 2018 at 10:43 am
A 72-year-old female with neovascular macular degeneration refractory to anti-vascular endothelial growth factor injections underwent photodynamic therapy and subsequently developed a macular hole (MH) associated with vitreomacular traction. After a period ... […]
Age-Related Macular Degeneration Pipeline Highlights Report 2018 - ResearchAndMarkets.com
on April 19, 2018 at 8:36 am
DUBLIN--(BUSINESS WIRE)--Apr 19, 2018--The "Age-Related Macular Degeneration Pipeline Highlights - 2018" report has been added to ResearchAndMarkets.com's offering. This report provides the most up-to-date information on key pipeline products in the global ... […]
Ask the Expert: Macular degeneration can lead to difficulty reading, recognizing faces and performing other fine tasks
on April 17, 2018 at 3:41 am
Macular degeneration is a disease of the eye that doesn’t lead to total blindness, but in its advanced stages can cause blind areas. This can make it hard for people to read, recognize faces and perform other tasks. Dr. Janet Sunness, a low vision and ... […]
Are you at risk for macular degeneration?
on April 13, 2018 at 6:51 am
Many people accept deteriorating eyesight as an inevitable part of getting older, but blurry or distorted vision – such as when straight lines appear wavy – could be signs of age-related macular degeneration. The condition is the most common cause of ... […]
New Retinal Implant Produces Hope of Cure for Macular Degeneration
on April 12, 2018 at 2:00 pm
Researchers say the implant process could eventually be a treatment for the loss of eyesight experienced by millions as they grow older. Photo: Getty Images “See you tomorrow,” you say casually at the end of the workday. Actually, you may not. […]
Healthy diet can be key to preventing age-related macular degeneration
on April 10, 2018 at 8:00 pm
There is no permanent cure for age-related macular degeneration (AMD), the leading cause of vision loss in adults ages 50 and older affecting about 10 million Americans. In addition to age, smoking and family history, a big risk factor for AMD is a poor diet. […]
Stan Lee: "I Have Macular Degeneration"
on April 10, 2018 at 6:39 am
"I am almost blind; I cannot see well at all and somehow they may have gotten me to sign something that I didn’t know what it was," Lee said. […]
Macular degeneration tied to aging immune cells
on April 8, 2018 at 5:02 pm
Aging immune cells increase the risk of age-related macular degeneration, a new study suggests. Studying mice and cells from patients, researchers found that as immune cells called macrophages age, they are more likely to contribute to the inflammation and ... […]
via Google News and Bing News